{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:10:36Z","timestamp":1793405436535,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,7,22]],"date-time":"2011-07-22T00:00:00Z","timestamp":1311292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s00109-011-0787-6","type":"journal-article","created":{"date-parts":[[2011,7,21]],"date-time":"2011-07-21T11:59:02Z","timestamp":1311249542000},"page":"1149-1161","source":"Crossref","is-referenced-by-count":69,"title":["Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54"],"prefix":"10.1007","volume":"89","author":[{"given":"Steven M.","family":"Rowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sloane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Ping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Backer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Buckley-Lanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Nudelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Belakhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsa","family":"Bebok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Schwiebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timor","family":"Baasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Bedwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,22]]},"reference":[{"key":"787_CR1","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","volume":"352","author":"SM Rowe","year":"2005","unstructured":"Rowe SM, Miller S, Sorscher EJ (2005) Cystic fibrosis. N Engl J Med 352:1992\u20132001","journal-title":"N Engl J Med"},{"key":"787_CR2","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1056\/NEJM199310283291804","volume":"329","author":"Anonymous","year":"1993","unstructured":"Anonymous (1993) Correlation between genotype and phenotype in patients with cystic fibrosis. The Cystic Fibrosis Genotype-Phenotype Consortium. N Engl J Med 329:1308\u20131313","journal-title":"N Engl J Med"},{"key":"787_CR3","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1172\/JCI117128","volume":"93","author":"T Shoshani","year":"1994","unstructured":"Shoshani T, Kerem E, Szeinberg A, Augarten A, Yahav Y, Cohen D, Rivlin J, Tal A, Kerem B (1994) Similar levels of mRNA from the W1282X and the delta F508 cystic fibrosis alleles, in nasal epithelial cells. J Clin Invest 93:1502\u20131507","journal-title":"J Clin Invest"},{"key":"787_CR4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.mcp.0000141247.22078.46","volume":"10","author":"E Kerem","year":"2004","unstructured":"Kerem E (2004) Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr Opin Pulm Med 10:547\u2013552","journal-title":"Curr Opin Pulm Med"},{"key":"787_CR5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/hmg\/10.3.291","volume":"10","author":"KM Keeling","year":"2001","unstructured":"Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM (2001) Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-l-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 10:291\u2013299","journal-title":"Hum Mol Genet"},{"key":"787_CR6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0496-467","volume":"2","author":"M Howard","year":"1996","unstructured":"Howard M, Frizzell RA, Bedwell DM (1996) Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 2:467\u2013469","journal-title":"Nat Med"},{"key":"787_CR7","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm1197-1280","volume":"3","author":"DM Bedwell","year":"1997","unstructured":"Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ (1997) Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 3:1280\u20131284","journal-title":"Nat Med"},{"key":"787_CR8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2174\/1568026033452131","volume":"3","author":"JB Tok","year":"2003","unstructured":"Tok JB, Bi L (2003) Aminoglycoside and its derivatives as ligands to target the ribosome. Curr Top Med Chem 3:1001\u20131019","journal-title":"Curr Top Med Chem"},{"key":"787_CR9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/jmbi.1995.0438","volume":"251","author":"B Bonetti","year":"1995","unstructured":"Bonetti B, Fu L, Moon J, Bedwell DM (1995) The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J Mol Biol 251:334\u2013345","journal-title":"J Mol Biol"},{"key":"787_CR10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1172\/JCI7866","volume":"104","author":"ER Barton-Davis","year":"1999","unstructured":"Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104:375\u2013381","journal-title":"J Clin Invest"},{"key":"787_CR11","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1017\/S1355838200000716","volume":"6","author":"M Manuvakhova","year":"2000","unstructured":"Manuvakhova M, Keeling K, Bedwell DM (2000) Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6:1044\u20131055","journal-title":"RNA"},{"key":"787_CR12","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","volume":"163","author":"JP Clancy","year":"2001","unstructured":"Clancy JP, Bebok Z, Ruiz F, King C, Jones J, Walker L, Greer H, Hong J, Wing L, Macaluso M et al (2001) Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 163:1683\u20131692","journal-title":"Am J Respir Crit Care Med"},{"key":"787_CR13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1741-7015-5-5","volume":"5","author":"I Sermet-Gaudelus","year":"2007","unstructured":"Sermet-Gaudelus I, Renouil M, Fajac A, Bidou L, Parbaille B, Pierrot S, Davy N, Bismuth E, Reinert P, Lenoir G et al (2007) In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 5:5\u201314","journal-title":"BMC Med"},{"key":"787_CR14","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1164\/ajrccm.161.3.9904116","volume":"161","author":"M Wilschanski","year":"2000","unstructured":"Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E (2000) A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 161:860\u2013865","journal-title":"Am J Respir Crit Care Med"},{"key":"787_CR15","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","volume":"349","author":"M Wilschanski","year":"2003","unstructured":"Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L et al (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349:1433\u20131441","journal-title":"N Engl J Med"},{"key":"787_CR16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1165\/rcmb.2006-0173OC","volume":"37","author":"JP Clancy","year":"2007","unstructured":"Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA et al (2007) No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 37:57\u201366","journal-title":"Am J Respir Cell Mol Biol"},{"key":"787_CR17","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","volume":"105","author":"M Du","year":"2008","unstructured":"Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM (2008) PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A 105:2064\u20132069","journal-title":"Proc Natl Acad Sci U S A"},{"key":"787_CR18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(08)61168-X","volume":"372","author":"E Kerem","year":"2008","unstructured":"Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M et al (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372:719\u2013727","journal-title":"Lancet"},{"key":"787_CR19","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1021\/jm801640k","volume":"52","author":"I Nudelman","year":"2009","unstructured":"Nudelman I, Rebibo-Sabbah A, Cherniavsky M, Belakhov V, Hainrichson M, Chen F, Schacht J, Pilch DS, Ben-Yosef T, Baasov T (2009) Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 52:2836\u20132845","journal-title":"J Med Chem"},{"key":"787_CR20","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1016\/j.bmcl.2006.09.013","volume":"16","author":"I Nudelman","year":"2006","unstructured":"Nudelman I, Rebibo-Sabbah A, Shallom-Shezifi D, Hainrichson M, Stahl I, Ben-Yosef T, Baasov T (2006) Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations. Bioorg Med Chem Lett 16:6310\u20136315","journal-title":"Bioorg Med Chem Lett"},{"key":"787_CR21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00439-007-0410-7","volume":"122","author":"A Rebibo-Sabbah","year":"2007","unstructured":"Rebibo-Sabbah A, Nudelman I, Ahmed ZM, Baasov T, Ben-Yosef T (2007) In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome. Hum Genet 122:373\u2013381","journal-title":"Hum Genet"},{"key":"787_CR22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/mthe.2000.0095","volume":"2","author":"X Wu","year":"2000","unstructured":"Wu X, Wakefield JK, Liu H, Xiao H, Kralovics R, Prchal JT, Kappes JC (2000) Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther 2:47\u201355","journal-title":"Mol Ther"},{"key":"787_CR23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1165\/rcmb.2006-0176OC","volume":"37","author":"SM Rowe","year":"2007","unstructured":"Rowe SM, Varga K, Rab A, Bebok Z, Byram K, Li Y, Sorscher EJ, Clancy JP (2007) Restoration of W1282X CFTR activity by enhanced expression. Am J Respir Cell Mol Biol 37:347\u2013356","journal-title":"Am J Respir Cell Mol Biol"},{"key":"787_CR24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pupt.2010.02.001","volume":"23","author":"SM Rowe","year":"2010","unstructured":"Rowe SM, Pyle LC, Jurkevante A, Varga K, Collawn J, Sloane PA, Woodworth B, Mazur M, Fulton J, Fan L et al (2010) DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol Ther 23:268\u2013278","journal-title":"Pulm Pharmacol Ther"},{"key":"787_CR25","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","volume":"106","author":"F Goor Van","year":"2009","unstructured":"Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A et al (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 106:18825\u201318830","journal-title":"Proc Natl Acad Sci U S A"},{"key":"787_CR26","doi-asserted-by":"crossref","first-page":"15222","DOI":"10.1021\/bi980436f","volume":"37","author":"JP Clancy","year":"1998","unstructured":"Clancy JP, Hong JS, Bebok Z, King SA, Demolombe S, Bedwell DM, Sorscher EJ (1998) Cystic fibrosis transmembrane conductance regulator (CFTR) nucleotide-binding domain 1 (NBD-1) and CFTR truncated within NBD-1 target to the epithelial plasma membrane and increase anion permeability. Biochemistry 37:15222\u201315230","journal-title":"Biochemistry"},{"key":"787_CR27","doi-asserted-by":"crossref","first-page":"L12","DOI":"10.1152\/ajplung.2002.282.1.L12","volume":"282","author":"BR Cobb","year":"2002","unstructured":"Cobb BR, Ruiz F, King CM, Fortenberry J, Greer H, Kovacs T, Sorscher EJ, Clancy JP (2002) A(2) adenosine receptors regulate CFTR through PKA and PLA(2). Am J Physiol Lung Cell Mol Physiol 282:L12\u2013L25","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"787_CR28","first-page":"628","volume":"52","author":"I Sermet-Gaudelus","year":"2002","unstructured":"Sermet-Gaudelus I, Vallee B, Urbin I, Torossi T, Marianovski R, Fajac A, Feuillet MN, Bresson JL, Lenoir G, Bernaudin JF, Edelman A (2002) Normal function of the cystic fibrosis conductance regulator protein can be associated with homozygous (delta)F508 mutation. Pediatr Res 52:628\u2013635","journal-title":"Pediatr Res"},{"key":"787_CR29","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1074\/jbc.M508131200","volume":"281","author":"A Jurkuvenaite","year":"2006","unstructured":"Jurkuvenaite A, Varga K, Nowotarski K, Kirk KL, Sorscher EJ, Li Y, Clancy JP, Bebok Z, Collawn JF (2006) Mutations in the amino terminus of the cystic fibrosis transmembrane conductance regulator enhance endocytosis. J Biol Chem 281:3329\u20133334","journal-title":"J Biol Chem"},{"key":"787_CR30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/ng0593-35","volume":"4","author":"R Ratcliff","year":"1993","unstructured":"Ratcliff R, Evans MJ, Cuthbert AW, MacVinish LJ, Foster D, Anderson JR, Colledge WH (1993) Production of a severe cystic fibrosis mutation in mice by gene targeting. Nat Genet 4:35\u201341","journal-title":"Nat Genet"},{"key":"787_CR31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00109-002-0363-1","volume":"80","author":"M Du","year":"2002","unstructured":"Du M, Jones JR, Lanier J, Keeling KM, Lindsey RJ, Tousson A, Bebok Z, Whitsett JA, Dey CR, Colledge WH et al (2002) Aminoglycoside suppression of a premature stop mutation in a Cftr\u2212\/\u2212 mouse carrying a human CFTR-G542X transgene. J Mol Med 80:595\u2013604","journal-title":"J Mol Med"},{"key":"787_CR32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00109-006-0045-5","volume":"84","author":"M Du","year":"2006","unstructured":"Du M, Keeling KM, Fan L, Liu X, Kovacs T, Sorscher E, Bedwell DM (2006) Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J Mol Med 84:573\u2013582","journal-title":"J Mol Med"},{"key":"787_CR33","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1074\/jbc.M806728200","volume":"284","author":"M Du","year":"2009","unstructured":"Du M, Keeling KM, Fan L, Liu X, Bedwell DM (2009) Poly-l-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model. J Biol Chem 284:6885\u20136892","journal-title":"J Biol Chem"},{"key":"787_CR34","doi-asserted-by":"crossref","first-page":"22578","DOI":"10.1074\/jbc.M401522200","volume":"279","author":"K Varga","year":"2004","unstructured":"Varga K, Jurkuvenaite A, Wakefield J, Hong JS, Guimbellot JS, Venglarik CJ, Niraj A, Mazur M, Sorscher EJ, Collawn JF, Bebok Z (2004) Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines. J Biol Chem 279:22578\u201322584","journal-title":"J Biol Chem"},{"key":"787_CR35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1165\/rcmb.2009-0281OC","volume":"43","author":"LC Pyle","year":"2009","unstructured":"Pyle LC, Fulton JC, Sloane PA, Backer K, Mazur M, Prasain J, Barnes S, Clancy JP, Rowe SM (2009) Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: potential use as a biomarker of deltaF508 cystic fibrosis transmembrane conductance regulator rescue. Am J Respir Cell Mol Biol 43:607\u2013616","journal-title":"Am J Respir Cell Mol Biol"},{"key":"787_CR36","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1164\/rccm.200509-1377OC","volume":"174","author":"M Wilschanski","year":"2006","unstructured":"Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E, Martin S, Corey M, Tsui LC, Durie P (2006) Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 174:787\u2013794","journal-title":"Am J Respir Crit Care Med"},{"key":"787_CR37","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2009.05.037","volume":"137","author":"MJ Bijvelds","year":"2009","unstructured":"Bijvelds MJ, Bot AG, Escher JC, De Jonge HR (2009) Activation of intestinal Cl\u2212 secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology 137:976\u2013985","journal-title":"Gastroenterology"},{"key":"787_CR38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200923030-00003","volume":"23","author":"SM Rowe","year":"2009","unstructured":"Rowe SM, Clancy JP (2009) Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. BioDrugs 23:165\u2013174","journal-title":"BioDrugs"},{"key":"787_CR39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/157016005774913149","volume":"3","author":"K Keeling","year":"2005","unstructured":"Keeling K, Bedwell DM (2005) Pharmacological suppression of premature stop mutations that cause genetic diseases. Current Pharmacogenomics 3:259\u2013269","journal-title":"Current Pharmacogenomics"},{"key":"787_CR40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-0-387-89382-2_6","volume-title":"Recoding: expansion of decoding rules enriches gene expression","author":"K Keeling","year":"2010","unstructured":"Keeling K, Bedwell DM (2010) Recoding therapies for genetic diseases. In: Gesteland R, Atkins J (eds) Recoding: expansion of decoding rules enriches gene expression. Springer, New York, pp 123\u2013146"},{"key":"787_CR41","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","volume":"67","author":"V Malik","year":"2010","unstructured":"Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, Al-Dahhak R, Lewis S, Shilling CJ, Kota J, Serrano-Munuera C et al (2010) Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 67:771\u2013780","journal-title":"Ann Neurol"},{"key":"787_CR42","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","volume":"43","author":"MP Mingeot-Leclercq","year":"1999","unstructured":"Mingeot-Leclercq MP, Tulkens PM (1999) Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 43:1003\u20131012","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR43","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1128\/AAC.38.11.2517","volume":"38","author":"T Hutchin","year":"1994","unstructured":"Hutchin T, Cortopassi G (1994) Proposed molecular and cellular mechanism for aminoglycoside ototoxicity. Antimicrob Agents Chemother 38:2517\u20132520","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR44","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1569-1993(10)60075-6","volume":"9","author":"SM Rowe","year":"2010","unstructured":"Rowe SM, Clancy JP, Boyle M, Van Goor F, Ordonez C, Dong Q, Campbell P, Ashlock M, Accurso F (2010) Parallel effects of VX-770 on transepithelial potential difference in vitro and in vivo. J Cyst Fibros 9:S20","journal-title":"J Cyst Fibros"},{"key":"787_CR45","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1172\/JCI118176","volume":"96","author":"SK Moestrup","year":"1995","unstructured":"Moestrup SK, Cui S, Vorum H, Bregengard C, Bjorn SE, Norris K, Gliemann J, Christensen EI (1995) Evidence that epithelial glycoprotein 330\/megalin mediates uptake of polybasic drugs. J Clin Invest 96:1404\u20131413","journal-title":"J Clin Invest"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-011-0787-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-011-0787-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-011-0787-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T22:49:11Z","timestamp":1712616551000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-011-0787-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,22]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1007\/s00109-011-0787-6","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,22]]}}}